Table III.
Effect of additional targeted biopsy identified by MRI on cancer detection rates.
| Characteristics | No. of patients | No. of cancer patients | Increase in the no. of cancer patients | Increase in the positive rate (%) |
|---|---|---|---|---|
| PSA (ng/ml) | ||||
| <4 | 56 | 12 | 3 | 3/56 (5.4) |
| 4–10 | 218 | 84 | 22 | 22/218 (10.1)a |
| ≥10 | 146 | 77 | 16 | 16/146 (11.0) |
| Prostate volume (ml) | ||||
| <30 | 105 | 52 | 5 | 5/105 (4.8) |
| 30–50 | 172 | 68 | 16 | 16/172 (9.3) |
| ≥50 | 143 | 53 | 20 | 20/143 (14.0)b |
| PSAD (ng/ml2) | ||||
| <0.12 | 80 | 16 | 5 | 5/80 (6.3) |
| 0.12–0.20 | 185 | 80 | 23 | 23/185 (12.4)c |
| ≥0.20 | 155 | 77 | 13 | 13/155 (8.4) |
| TRUS | ||||
| Normal | 302 | 100 | 33 | 33/302 (10.9)d |
| Abnormal | 118 | 73 | 8 | 8/118 (6.8) |
| DRE | ||||
| Normal | 368 | 139 | 37 | 37/368 (10.1)e |
| Abnormal | 52 | 34 | 4 | 4/52 (7.7) |
| Overall | 420 | 173 | 41 | 41/420 (9.8)f |
These values were calculated by Chi-square test. MRI, magnetic resonance imaging; PSA, prostate-specific antigen; PSA density; DRE, digital rectal examination; TRUS, transrectal ultrasound.
a–e
The positive rate was significantly improved, with P-values of 0.0256, 0.0099, 0.0133, 0.0027, 0.0037 and 0.0033, respectively.